

Executive Officer Notice

Pan-Canadian Competitive Value Price Initiative for Generic Drugs

March 10, 2015

Provinces and territories are continuing to work together to lower generic drug prices through the Pan-Canadian Competitive Value Price Initiative for Generic Drugs, which is a coordinated approach to price setting for generic drugs across Canada's provinces and territories (with the exception of Quebec).

In the past two years, the work of the Initiative resulted in the lowering of the prices of ten (10) high expenditure molecules to 18% of the brand price. The prices for these ten molecules will remain at 18% of the brand price for one (1) additional year.

In 2015, another four (4) generic molecules have been selected to be reduced to 18% of the brand price:

- Clopidogrel Bisulfate
- Gabapentin
- Metformin HCL
- Olanzapine

The prices for these four generic molecules will have new Drug Benefit Prices, effective April 1, 2015.

The Ministry has posted a new file (Edition No. 42, Summary of Changes – April 1, 2015) with the listing changes for pharmacies to download and review. It is accessible from the Ministry's website at: http://www.health.gov.on.ca/en/pro/programs/drugs/edition_42.aspx

We appreciate your attention to this matter and continued cooperation in making these benefit adjustments.